Paper Details

  1. Home
  2. Paper Details

The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.

Author: IsraelHeike, NeebLars, RaffaelliBianca, ReuterUwe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Lasmiditan, a selective 5-HT1F receptor agonist, is a novel acute migraine treatment. This article explores the clinical efficacy and safety of lasmiditan, highlighting its potential benefits for patients with cardiovascular risks who cannot take traditional triptan medications.
Paper Details　
Original Abstract of the Article :
Migraine is among the most disabling disorders worldwide, with a significant therapeutic need. Triptans are drugs of choice in the acute attack treatment, but they are contraindicated in patients with vascular conditions due to their potential vasoconstrictive properties. Further limitations include...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14656566.2017.1361406

データ提供：米国国立医学図書館（NLM）

Lasmiditan: A Novel Treatment for Migraine Without Vasoconstriction

Migraine headaches are a debilitating condition affecting millions worldwide. This research examines the efficacy and safety of lasmiditan, a novel migraine treatment that acts as a 5-HT1F receptor agonist, in the acute treatment of migraine. The authors explore the potential of lasmiditan as an alternative to triptans, which are contraindicated in patients with cardiovascular conditions due to their vasoconstrictive properties.

Lasmiditan: A Promising Alternative for Migraine Relief

The study provides encouraging evidence that lasmiditan, a non-vasoconstrictive agent, is effective in treating acute migraine attacks. The researchers found that lasmiditan showed significant improvement in headache response compared to placebo, opening up new possibilities for migraine management, particularly in patients with cardiovascular risk factors.

A New Era in Migraine Management

This research is a beacon of hope in the fight against migraine. By offering a safe and effective alternative to triptans, lasmiditan could significantly benefit patients with migraine, particularly those with cardiovascular concerns. It's like discovering a hidden oasis in the desert of migraine pain, providing a welcome respite from the debilitating effects of migraine headaches.

Dr.Camel's Conclusion

This study is like a desert traveler discovering a hidden oasis, offering a safe and effective way to combat migraine pain. Lasmiditan's non-vasoconstrictive properties open up new avenues for treating migraine, particularly for those with cardiovascular concerns. This research is a significant step forward in the quest to find effective and safe migraine treatments.

Date :
  1. Date Completed 2017-12-04
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

28749698

DOI: Digital Object Identifier

10.1080/14656566.2017.1361406

Related Literature

Article Analysis
・Side Effects of lasmiditan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.